GSK forays into the cardiovascular segment by launching a beta-blocker Carzec (carvedilol)
GlaxoSmithKline Pharmaceuticals Limited(GSK) has launched Carzec (carvedilol), a beta-blocker indicated in patients with heart failure and for the management of hypertension. Carzec (carvedilol) acts by reducing the workload on the heart, thus reducing blood pressure. In addition to lowering blood pressure, Carzec has anti-oxidant and cardioprotective properties and is glucose and lipid friendly.
According to Dr. Sadhna Joglekar, Vice President, Medical Affairs and Clinical Research Carvedilol will provide physicians an effective option to manage patients with hypertension, as well as those with chronic heart failure.
GSK is partnering with the physician community across India to develop a strong understanding of the issues surrounding under-use of beta-blockers in the management of heart failure. There is tremendous potential to impact the burden of risk factors for heart disease, particularly hypertension in India.
High blood pressure or hypertension is directly associated with risks of several types of cardiovascular disease but can be controlled conveniently and effectively. Hypertension or high blood pressure is steadily increasing in India. The estimated burden of hypertension in India was 118 million in 2000, with a projected increase to 213 million in 2025.
Series of seminars on "Evidence based approach in the management of Heart Failure, Hypertension and co-morbidities" will be held in Chennai, Mumbai, Kolkata, Bangalore and Delhi betwwen August 26 to 30. The symposia will be addressed by Dr. Michael B. Fowler, M.B., F.R.C.P., Professor- Medicine, Director- Heart Failure Program, and Medical Director- Cardiomyopathy Center in Cardiovascular Medicine Division, at School of Medicine, Stanford University, California.